Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response

<jats:title>Abstract</jats:title><jats:p>Transfer of convalescent plasma (CP) had been proposed early during the SARS-CoV-2 pandemic as an accessible therapy, yet trial results worldwide have been mixed, potentially due to the heterogeneous nature of CP. Here we perform deep profil...

Full description

Bibliographic Details
Main Authors: Herman, Jonathan D, Wang, Chuangqi, Loos, Carolin, Yoon, Hyunah, Rivera, Johanna, Eugenia Dieterle, M, Haslwanter, Denise, Jangra, Rohit K, Bortz, Robert H, Bar, Katharine J, Julg, Boris, Chandran, Kartik, Lauffenburger, Douglas, Pirofski, Liise-anne, Alter, Galit
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering
Format: Article
Language:English
Published: Springer Science and Business Media LLC 2023
Online Access:https://hdl.handle.net/1721.1/147864
Description
Summary:<jats:title>Abstract</jats:title><jats:p>Transfer of convalescent plasma (CP) had been proposed early during the SARS-CoV-2 pandemic as an accessible therapy, yet trial results worldwide have been mixed, potentially due to the heterogeneous nature of CP. Here we perform deep profiling of SARS-CoV-2-specific antibody titer, Fc-receptor binding, and Fc-mediated functional assays in CP units, as well as in plasma from hospitalized COVID-19 patients before and after CP administration. The profiling results show that, although all recipients exhibit expanded SARS-CoV-2-specific humoral immune responses, CP units contain more functional antibodies than recipient plasma. Meanwhile, CP functional profiles influence the evolution of recipient humoral immunity in conjuncture with the recipient’s pre-existing SARS-CoV2-specific antibody titers: CP-derived SARS-CoV-2 nucleocapsid-specific antibody functions are associated with muted humoral immune evolution in patients with high titer anti-spike IgG. Our data thus provide insights into the unexpected impact of CP-derived functional anti-spike and anti-nucleocapsid antibodies on the evolution of SARS-CoV-2-specific response following severe infection.</jats:p>